Mitsubishi
Bain Capital Acquires Mitsubishi Tanabe Pharma for $3.3 Billion in Strategic Japanese Pharma Investment
Bain Capital, Mitsubishi Tanabe Pharma, acquisition, Japanese pharmaceutical industry, carve-out transaction, private equity, life sciences investment
Mitsubishi Tanabe and Dewpoint Therapeutics Collaborate on $480M ALS Treatment Development
ALS treatment, Dewpoint Therapeutics, Mitsubishi Tanabe Pharma Corporation, TDP-43, small molecule condensate modulator, biobucks deal